Cosmetics Europe is preparing for challenges amid EU regulatory movement to clamp down on endocrine disruptors while also strategizing to defend CMR (carcinogenic, mutagenic or reprotoxic) substances within what could be a narrow timeframe for industry to build its case.
In a December interview, the trade group’s Director-General John Chave noted that the European Commission’s recent (and long overdue)